Tumor Antigen | YesPress

Browse all tags

ceo2909 saas2438 ai1735 fintech1458 founder1251 b2b1079 b2b saas892 san francisco823 co-founder816 san-francisco799 y combinator770 startup734 machine learning666 enterprise software631 stanford603 series a590 venture capital577 biotech543 cybersecurity535 healthtech479 new york startup469 ai agents458 enterprise-software446 generative ai437 digital health434 agentic ai397 silicon-valley389 d2c386 silicon valley381 ecommerce380 machine-learning373 startup founder360 california351 entrepreneur350 new york347 edtech344 venture-capital340 climate tech328 newsletter321 mit302 proptech302 robotics294 y-combinator281 san francisco startup278 enterprise ai276 series b273 developer tools266 computer vision255 oncology252 open-source248 series-a244 harvard242 supply chain241 sustainability240 iot232 enterprise229 compliance225 biotechnology224 workflow automation223 telehealth217 founder ceo216 developer-tools213 healthcare213 insurtech212 blockchain211 devops208 medical devices206 series-b206 logistics200 forbes 30 under 30194 llm193 uc berkeley189 author188 generative-ai188 clean energy187 deep tech187 web3185 a16z183 cloud183 drug discovery182 no-code182 b2c176 life sciences176 artificial intelligence175 manufacturing174 crm172 payments170 general partner169 healthcare ai169 serial entrepreneur167 seed funding164 open source163 automation160 podcast160 hardware159 digital transformation158 unicorn158 marketplace153 predictive analytics152 infrastructure151

Often tagged with

biotech1 cancer-immunotherapy1 single-cell-genomics1 founder-ceo1 immuno-oncology1 precision-medicine1 startup1 stanford1 harvard1 car-t1 bispecific-antibodies1 drug-discovery1 machine-learning1 computational-biology1

Tagged: tumor-antigen

1 result

Sort

Founder · Executive · Scientist

Kevin Parker

Kevin Parker, Ph.D. is the co-founder and CEO of Cartography Biosciences, a South San Francisco-based oncology company using single-cell genomics and AI to map the tumor antigen landscape and build precision immunotherapies. A Harvard and Stanford alumnus who founded the company straight out of his PhD, Parker has raised $124M in total funding, struck a landmark collaboration with Gilead Sciences, received FDA IND approval for his lead drug CBI-1214, and dosed the first patient in a Phase 1 colorectal cancer trial in early 2026 - all before most scientists finish a second postdoc.

biotech · cancer-immunotherapyRead →